The Gulf conflict has disrupted global supply chains, pushed...
REITs have changed the way commercial real estate is owned a...
What really powers the cloud? Behind every Google search, A...
What really powers the cloud? Behind every Google search, A...
Luxury real estate is one of the most talked-about segments ...
Syngenta's advisers are targeting a valuation of at least USD 66 billion for the Swiss-Chinese agrochemicals company's planned Hong Kong initial public offering (IPO), according to people familiar with the matter cited by Reuters. The listing could value the company at between USD 66 billion and USD 88 billion, based on a multiple of 15 to 20 times its earnings before interest, tax, depreciation and amortisation. Syngenta reported EBITDA of USD 4.4 billion in 2025, a 17% increase from the previous year. The IPO is expected to take place in early 2027.
Syngenta's advisers are targeting a valuation of at least USD 66 billion for the Swiss-Chinese agrochemicals company's planned Hong Kong stock market listing, which is likely to take place in early 2027, according to two people familiar with the matter cited by Reuters.
The Basel-based company, which manufactures seeds and crop protection products, is controlled by China's state-owned Sinochem. Banks advising on the offering are marketing Syngenta at a valuation multiple of 15 to 20 times its expected 2026 earnings before interest, tax, depreciation and amortisation (EBITDA).
UBS and China International Capital Corporation (CICC) are leading the IPO process, while China CITIC Bank and Bank of America are also involved. The offering is expected to rank among the world's largest IPOs when completed.
Syngenta reported EBITDA of USD 4.4 billion in 2025, marking a 17% increase from the previous year. Applying a valuation multiple of 15 times that figure gives the company a valuation of USD 66 billion, while a multiple of 20 times implies a valuation of USD 88 billion. The advisers are, however, using projected 2026 earnings to market the offering.
According to additional Reuters reporting, Syngenta plans to sell a stake of 10% to 20% through the IPO, which could raise between USD 5 billion and USD 10 billion. The proceeds are expected to be used to reduce debt and fund investments in seeds and crop protection products. The company has already filed for the proposed listing.
The IPO process includes discussions with investors in Shanghai, Hong Kong and Beijing, followed by planned investor marketing in Frankfurt and London. Sources cited by Reuters said a listing before the end of 2026 remained possible, although an early-2027 debut was considered more likely.
Syngenta and UBS declined to comment on the valuation plans. China CITIC Bank, Bank of America and CICC did not immediately respond to requests for comment.
The proposed listing would also revive Sinochem's efforts to take Syngenta public after the company withdrew a planned Shanghai listing in 2024. Sinochem acquired Syngenta for USD 43 billion in 2017, before being reorganised under the state-owned chemical group in 2021.
Syngenta's valuation will depend on investor demand, its earnings outlook and the terms of the final offering. The company operates in the seeds and crop protection markets, competing with groups such as BASF, Bayer and Corteva. Its product portfolio includes seeds, herbicides, insecticides, fungicides, biological products and digital farming solutions.
The proposed Hong Kong listing will be an important test of investor appetite for a major agricultural technology and chemicals business, particularly as markets assess company valuations and growth prospects. Syngenta's planned use of IPO proceeds to reduce debt and invest in seeds and crop protection products will also be relevant to investors evaluating the offering. The next key developments will be the final listing timetable, the size of the stake offered and the valuation investors are willing to support. Until the offering terms ar
Source Reuters
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
13th Nov, 2026
12th Nov, 2026
9th Nov, 2026